Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor

Anesthesiology

Volumn 110, Issue 6, 2009, Pages 1244-1252

  Fagerlund, Malin Jonsson ^a   Dabrowski, Michael ^b   Eriksson, Lars I ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 DIMETHYL 4 PHENYLPIPERAZINIUM; ACETYLCHOLINE; ATRACURIUM; MIVACURIUM; NEUROMUSCULAR BLOCKING AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA1; NICOTINIC RECEPTOR BETA1; NICOTINIC RECEPTOR DELTA; NICOTINIC RECEPTOR EPSILON; ORG NC 97; PANCURONIUM; ROCURONIUM; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG; VECURONIUM; 1,1 DIMETHYL 4 PHENYLPIPERAZINIUM IODIDE; DNA; NICOTINIC RECEPTOR BLOCKING AGENT;

ACETYLCHOLINE RELEASE; ANIMAL TISSUE; ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IC 50; MOLECULAR CLONING; MOLECULAR INTERACTION; NEUROMUSCULAR BLOCKING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; VOLTAGE CLAMP; XENOPUS; ADULT; ALGORITHM; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; ELECTROPHYSIOLOGY; GENETICS; IN VITRO STUDY; METABOLISM; OOCYTE; PATCH CLAMP; SKELETAL MUSCLE; XENOPUS LAEVIS;

ACETYLCHOLINE; ADULT; ALGORITHMS; ANIMALS; CLONING, MOLECULAR; DIMETHYLPHENYLPIPERAZINIUM IODIDE; DNA; ELECTROPHYSIOLOGY; HUMANS; MUSCLE, SKELETAL; NEUROMUSCULAR NONDEPOLARIZING AGENTS; NICOTINIC ANTAGONISTS; OOCYTES; PATCH-CLAMP TECHNIQUES; RECEPTORS, NICOTINIC; XENOPUS LAEVIS;

EID: 67049173266     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e31819fade3     Document Type: Article

References (20)

1. Jonsson M, Gurley D, Dabrowski M, Larsson O, Johnson EC, Eriksson LI: Distinct pharmacological properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: A possible mechanism behind the train-of-four fade. AANESTHESIOIOGY 2006; 105:521-33
2. Bowman WC: Neuromuscular block. Br J Pharmacol 2006; l47(Suppl 1): S277-86
3. Karlin A: Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci 2002; 3:102-14
4. Lindstrom JM: Nicotinic acetylcholine receptors of muscles and nerves: Comparison of their structures, functional roles, and vulnerability to pathology. Ann N Y Acad Sci 2003; 998:41-52
5. Tsuneki H, Kimura I, Dezaki K, Kimura M, Sala C, Fumagalli G: Immuno- histochemical localization of neuronal nicotinic receptor subtypes at the pre- and postjunctional sites in mouse diaphragm muscle. Neurosci Lett 1995; 196:13-6
6. Tsuneki H, Salas R, Dani JA: Mouse muscle denervation increases expression of an alpha7 nicotinic receptor with unusual pharmacology. J Physiol 2003; 547:169-79
7. Mishina M, Takai T, Imoto K, Noda M, Takahashi T, Numa S, Methfessel C, Sakmann B: Molecular distinction between fetal and adult forms of muscle acetylcholine receptor. Nature 1986; 321:406-11
8. Teichert RW, Rivier J, Torres J, Dykert J, Miller C, Olivera BM: A uniquely selective inhibitor of the mammalian fetal neuromuscular nicotinic acetylcholine receptor. J Neurosci 2005; 25:732-6
9. Yost CS, Winegar BD: Potency of agonists and competitive antagonists on adult- and fetal-type nicotinic acetylcholine receptors. Cell Mol Neurobiol 1997;17:35-50
10. Paul M, Kindler CH, Fokt RM, Dresser MJ, Dipp NC, Yost CS: The potencyof new muscle relaxants on recombinant muscle-type acetylcholine receptors. Anesth Analg 2002; 94:597-603
11. Garland CM, Foreman RC, Chad JE, Holden-Dye L, Walker RJ: The actions of muscle relaxants at nicotinic acetylcholine receptor isoforms. Eur J Pharmacol 1998; 357:83-92
12. Purohit PG, Tate RJ, Pow E, Hill D, Connolly JG: The role of the amino acid residue at alpha1:189 in the binding of neuromuscular blocking agents to mouse and human muscle nicotinic acetylcholine receptors. Br J Pharmacol 2007; 150:920-31
13. Lowenick CV, Krampfl K, Schneck H, Kochs E, BuflerJ: Open channel and competitive block of nicotinic receptors by pancuronium and atracurium. Eur J Pharmacol 2001; 413:31-5
14. Fletcher GH, Steinbach JH: Ability of nondepolarizing neuromuscular blocking drugs to act as partial agonists at fetal and adult mouse muscle nicotinic receptors. Mol Pharmacol 1996; 49:938-47
15. Jonsson M, Dabrowski M, Gurley DA, Larsson O, Johnson EC, Fredholm BB, Eriksson LI: Activation and inhibition of human muscular and neuronal nicotinic acetylcholine receptors by succinylcholine. ANESTHESIOIOGY 2006; 104:724-33
16. Chavez-Noriega LE, CronaJH, Washburn MS, Urrutia A, Elliott KJ, Johnson EC:Pharmacological characterization of recombinant human neuronal nicotinic acetyl- choline receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J Pharmacol Exp Ther 1997; 280: 346-56
17. Hatton CJ, Shelley C, Brydson M, Beeson D, Colquhoun D: Properties of the human muscle nicotinic receptor, and of the slow-channel myasthenic syndrome mutant epsilonL221F, inferred from maximum likelihood fits. J Physiol 2003; 547:729-60
18. Sine SM, Taylor P: Relationship between reversible antagonist occupancy and the functional capacity of the acetylcholine receptor. J Biol Chem 1981;256:6692-9
19. ]19. Lape R, Colquhoun D, Sivilotti LG: On the nature of partial agonism in the nicotinic receptor superfamily. Nature 2008; 454:722-7
20. Yost CS, Dodson BA: Inhibition of the nicotinic acetylcholine receptor by barbiturates and by procaine: Do they act at different sites? Cell Mol Neurobiol 1993; 13:159-72